Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

1956 ARTÍCULOS , VIENDO DEL 1 AL 15

Placebo effects in therapeutic outcomes

Horin AP, Lee KM, Colloca L.

Curr Clin Pharmacol. 2014 May;9(2):116-22. doi: 10.2174/1574884708999140101145528.

Citalopram-associated gambling: a case report

Cuomo I, Kotzalidis GD, Caccia F, Danese E, Manfredi G, Girardi P.

J Gambl Stud. 2014 Jun;30(2):467-73. doi: 10.1007/s10899-013-9360-2.

Clinical aspects of comorbid schizophrenia and idiopathic Parkinson's disease

de Jong MH, Zemel D, Van Gool AR.

Clin Schizophr Relat Psychoses. 2014 Apr;8(1):36-40.

FDG PET/CT images demonstrating Fournier gangrene with bilateral pelvic muscle extension in a patient with recurrent rectosigmoid cancer

Hsu CT, Kao PF, Huang CC, Huang HH, Lee JK.

Clin Nucl Med. 2014 Jan;39(1):52-3. doi: 10.1097/RLU.0b013e3182868077.

Increased 99mTc TRODAT-1 uptake in anaplastic oligodendroglioma

Chen YR, Hsieh TC, Yen KY, Kao CH.

Clin Nucl Med. 2014 Jan;39(1):e104-5. doi: 10.1097/RLU.0b013e3182815f43.

Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disorders

Ma Z, Liu H, Wu B.

Br J Clin Pharmacol. 2014 Mar;77(3):410-20. doi: 10.1111/bcp.12169.

TDP-43 pathology is present in most post-encephalitic parkinsonism brains

Ling H, Holton JL, Lees AJ, Revesz T.

Neuropathol Appl Neurobiol. 2014 Aug;40(5):654-7. doi: 10.1111/nan.12067.

Recent advances in Parkinson’s disease genetics

Lubbe S, Morris HR.

J Neurol. 2014 Feb;261(2):259-66. doi: 10.1007/s00415-013-7003-2.

Emerging trends in the epidemiology of melanoma

Nikolaou V, Stratigos AJ.

Br J Dermatol. 2014 Jan;170(1):11-9. doi: 10.1111/bjd.12492.

TRYCAT pathways link peripheral inflammation, nicotine, somatization and depression in the etiology and course of Parkinson's disease

Anderson G, Maes M.

CNS Neurol Disord Drug Targets. 2014 Feb;13(1):137-49. doi: 10.2174/18715273113129990082.

The multiple pharmaceutical potential of curcumin in Parkinson's disease

Ji HF, Shen L.

CNS Neurol Disord Drug Targets. 2014 Mar;13(2):369-73. doi: 10.2174/18715273113129990077.

The incidental suggestive meningioma presenting as high 18F FP-CIT uptake on PET/CT study

Song IU, Lee SH, Chung YA.

Clin Nucl Med. 2014 Jan;39(1):e97-8. doi: 10.1097/RLU.0b013e3182815d16.

Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives

Herradón G, Pérez-García C.

Br J Pharmacol. 2014 Feb;171(4):837-48. doi: 10.1111/bph.12312.

Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases

Hölscher C.

J Endocrinol. 2014 Mar 7;221(1):T31-41. doi: 10.1530/JOE-13-0221. Print 2014 Apr.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias